Zhangzhou Pientzehuang Pharmaceutical (600436.SS) Earnings Analysis

Zhangzhou Pientzehuang Pharmaceutical (600436.SS) next reports earnings on 2026-08-29, consensus EPS 0.91 CNY. Last quarter (2026-04-30) it missed with EPS 1.23 CNY vs 1.78 CNY est (-30.9%). It has beaten estimates in 2/7 recent quarters (29%). Trailing P/E 43.38.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 600436.SS next report earnings?

Next earnings date2026-08-29
Consensus EPS estimate0.91 CNY
Revenue estimate2.00B

600436.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-301.23 CNY1.78 CNY-30.9%Miss
2026-04-290.05 CNY1.11 CNY-95.5%Miss
2025-10-171.14 CNY1.53 CNY-25.5%Miss
2025-08-220.729 CNY1.27 CNY-42.6%Miss
2025-01-240.48 CNY0.4762 CNY+0.8%Beat
2024-10-181.6 CNY1.45 CNY+10.3%Beat
2024-07-241.23 CNY1.53 CNY-19.6%Miss

Beat rate: 2/7 (29%) over reported quarters with consensus data.

600436.SS valuation and analyst view

Trailing P/E43.38
Trailing EPS3.147 CNY
Price / book5.43
Dividend yield2.36%
Market cap84.46B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Zhangzhou Pientzehuang Pharmaceutical (600436.SS)'s next earnings date?

Zhangzhou Pientzehuang Pharmaceutical is next scheduled to report on 2026-08-29, with a consensus EPS estimate of 0.91 CNY and revenue estimate of 2.00B.

Did 600436.SS beat earnings last quarter?

In its 2026-04-30 report, 600436.SS posted EPS of 1.23 CNY versus a 1.78 CNY estimate — a miss of 30.9%.

What is 600436.SS's earnings track record?

Over the last 7 reported quarters with consensus data, 600436.SS beat estimates 2 times (29%).

What is 600436.SS's current P/E ratio and EPS?

600436.SS trades at a trailing P/E of 43.38 on trailing EPS of 3.1471698394950502 CNY.

What do analysts rate 600436.SS?

600436.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.